SCHEMBL378669

SCHEMBL378669

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)c4ccc(F)cc4)(c4ccccc4)CC3)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.41
NPY1R P25929 1/20 0.41
SLC6A4 P31645 1/20 0.41
TSHR P16473 2/20 0.41
BDKRB1 P46663 2/20 0.40
SCD5 Q86SK9 1/20 0.40
TACR3 P29371 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
NPY2R P49146 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396983 0.98 TACR1 (0.40) TACR1NPY1RSLC6A4TSHRBDKRB1
SCHEMBL13092251 0.97 BDKRB1 (0.40) TACR1NPY1RSLC6A4TSHRBDKRB1
SCHEMBL379355 0.96 TACR3 (0.41) TACR1NPY1RSLC6A4BDKRB1TACR3
SCHEMBL378915 0.94 TSHR (0.43) SLC6A4TSHRBDKRB1SCD5MEN1
SCHEMBL13092272 0.92 TACR3 (0.42) NPY1RSLC6A4TSHRBDKRB1SCD5
SCHEMBL395363 0.91 THRB (0.43) TACR1TSHRBDKRB1SCD5CYP2C9
SCHEMBL7908720 0.91 CTSL (0.42) TACR1TSHRBDKRB1SCD5TACR3
SCHEMBL378830 0.90 BDKRB1 (0.42) TACR1BDKRB1TACR3CYP1A2CYP2C9
SCHEMBL379059 0.89 STAT3 (0.42) TACR1NPY1RSLC6A4TSHR
SCHEMBL13092367 0.88 TACR3 (0.40) BDKRB1TACR3CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TACR1 19/4885NPY1R 298/4885SLC6A4 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.